Soluble immune mediators in POEMS syndrome with pulmonary hypertension

Case report and review of the literature

Loryn Feinberg, Donald Temple, Eduardo De Marchena, Roberto Patarca, Alberto Mitrani

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

POEMS syndrome is a plasma cell dyscrasia that presents with numerous complications, one of which is rarely pulmonary hypertension. Here we present a case of POEMS syndrome with pulmonary hypertension who improved with steroids and six rounds of plasmapheresis done over 1 month, and we document the baseline immune mediator status and the changes associated with the therapeutic intervention. Serum levels of soluble immune mediators such as interleukin (IL)-5, IL-8, IL-10, and eotaxin were normal at baseline and throughout therapy, whereas those of tumor necrosis factor (TNF)-α, soluble TNF-receptor type I (sTNF-RI), IL-6, interferon (IFN)-γ, IL-2, and sIL-2R, which were abnormally high at baseline normalized with steroids and plasmapheresis. Serum levels of sIL-6R, which were abnormally low at baseline, increased to normal after therapy. The latter results pinpoint not only potential mediators of the systemic manifestations of POEMS syndrome with pulmonary hypertension but also relevant markers in patient follow-up. In this respect, IL-6 has been involved in the pathogenesis of multiple myeloma and Castleman's disease, and the interplay between abnormally high levels of IL-6 and abnormally low levels of its soluble receptor, deficiencies that corrected with therapy in this patient, appears to be particularly relevant to the pathogenic manifestations of POEMS syndrome with pulmonary hypertension. These findings are discussed in the context of our current knowledge of the pathogenesis of pulmonary hypertension and of potential new therapeutic modalities for POEMS syndrome with pulmonary hypertension.

Original languageEnglish
Pages (from-to)293-302
Number of pages10
JournalCritical Reviews in Oncogenesis
Volume10
Issue number4
StatePublished - Dec 1 1999

Fingerprint

POEMS Syndrome
Pulmonary Hypertension
Interleukin-6
Plasmapheresis
Steroids
Receptors, Tumor Necrosis Factor, Type I
Giant Lymph Node Hyperplasia
Therapeutics
Paraproteinemias
Interleukin-5
Serum
Multiple Myeloma
Interleukin-8
Interleukin-10
Interferons
Interleukin-2
Tumor Necrosis Factor-alpha

Keywords

  • Cytokines
  • Interleukin-6
  • Plasma cell dyscrasias
  • Soluble cytokine receptors
  • Soluble interleukin-6 receptor

ASJC Scopus subject areas

  • Cancer Research

Cite this

Soluble immune mediators in POEMS syndrome with pulmonary hypertension : Case report and review of the literature. / Feinberg, Loryn; Temple, Donald; De Marchena, Eduardo; Patarca, Roberto; Mitrani, Alberto.

In: Critical Reviews in Oncogenesis, Vol. 10, No. 4, 01.12.1999, p. 293-302.

Research output: Contribution to journalArticle

Feinberg, Loryn ; Temple, Donald ; De Marchena, Eduardo ; Patarca, Roberto ; Mitrani, Alberto. / Soluble immune mediators in POEMS syndrome with pulmonary hypertension : Case report and review of the literature. In: Critical Reviews in Oncogenesis. 1999 ; Vol. 10, No. 4. pp. 293-302.
@article{6494738aaa224115be140d7f5c131a4a,
title = "Soluble immune mediators in POEMS syndrome with pulmonary hypertension: Case report and review of the literature",
abstract = "POEMS syndrome is a plasma cell dyscrasia that presents with numerous complications, one of which is rarely pulmonary hypertension. Here we present a case of POEMS syndrome with pulmonary hypertension who improved with steroids and six rounds of plasmapheresis done over 1 month, and we document the baseline immune mediator status and the changes associated with the therapeutic intervention. Serum levels of soluble immune mediators such as interleukin (IL)-5, IL-8, IL-10, and eotaxin were normal at baseline and throughout therapy, whereas those of tumor necrosis factor (TNF)-α, soluble TNF-receptor type I (sTNF-RI), IL-6, interferon (IFN)-γ, IL-2, and sIL-2R, which were abnormally high at baseline normalized with steroids and plasmapheresis. Serum levels of sIL-6R, which were abnormally low at baseline, increased to normal after therapy. The latter results pinpoint not only potential mediators of the systemic manifestations of POEMS syndrome with pulmonary hypertension but also relevant markers in patient follow-up. In this respect, IL-6 has been involved in the pathogenesis of multiple myeloma and Castleman's disease, and the interplay between abnormally high levels of IL-6 and abnormally low levels of its soluble receptor, deficiencies that corrected with therapy in this patient, appears to be particularly relevant to the pathogenic manifestations of POEMS syndrome with pulmonary hypertension. These findings are discussed in the context of our current knowledge of the pathogenesis of pulmonary hypertension and of potential new therapeutic modalities for POEMS syndrome with pulmonary hypertension.",
keywords = "Cytokines, Interleukin-6, Plasma cell dyscrasias, Soluble cytokine receptors, Soluble interleukin-6 receptor",
author = "Loryn Feinberg and Donald Temple and {De Marchena}, Eduardo and Roberto Patarca and Alberto Mitrani",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "10",
pages = "293--302",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "4",

}

TY - JOUR

T1 - Soluble immune mediators in POEMS syndrome with pulmonary hypertension

T2 - Case report and review of the literature

AU - Feinberg, Loryn

AU - Temple, Donald

AU - De Marchena, Eduardo

AU - Patarca, Roberto

AU - Mitrani, Alberto

PY - 1999/12/1

Y1 - 1999/12/1

N2 - POEMS syndrome is a plasma cell dyscrasia that presents with numerous complications, one of which is rarely pulmonary hypertension. Here we present a case of POEMS syndrome with pulmonary hypertension who improved with steroids and six rounds of plasmapheresis done over 1 month, and we document the baseline immune mediator status and the changes associated with the therapeutic intervention. Serum levels of soluble immune mediators such as interleukin (IL)-5, IL-8, IL-10, and eotaxin were normal at baseline and throughout therapy, whereas those of tumor necrosis factor (TNF)-α, soluble TNF-receptor type I (sTNF-RI), IL-6, interferon (IFN)-γ, IL-2, and sIL-2R, which were abnormally high at baseline normalized with steroids and plasmapheresis. Serum levels of sIL-6R, which were abnormally low at baseline, increased to normal after therapy. The latter results pinpoint not only potential mediators of the systemic manifestations of POEMS syndrome with pulmonary hypertension but also relevant markers in patient follow-up. In this respect, IL-6 has been involved in the pathogenesis of multiple myeloma and Castleman's disease, and the interplay between abnormally high levels of IL-6 and abnormally low levels of its soluble receptor, deficiencies that corrected with therapy in this patient, appears to be particularly relevant to the pathogenic manifestations of POEMS syndrome with pulmonary hypertension. These findings are discussed in the context of our current knowledge of the pathogenesis of pulmonary hypertension and of potential new therapeutic modalities for POEMS syndrome with pulmonary hypertension.

AB - POEMS syndrome is a plasma cell dyscrasia that presents with numerous complications, one of which is rarely pulmonary hypertension. Here we present a case of POEMS syndrome with pulmonary hypertension who improved with steroids and six rounds of plasmapheresis done over 1 month, and we document the baseline immune mediator status and the changes associated with the therapeutic intervention. Serum levels of soluble immune mediators such as interleukin (IL)-5, IL-8, IL-10, and eotaxin were normal at baseline and throughout therapy, whereas those of tumor necrosis factor (TNF)-α, soluble TNF-receptor type I (sTNF-RI), IL-6, interferon (IFN)-γ, IL-2, and sIL-2R, which were abnormally high at baseline normalized with steroids and plasmapheresis. Serum levels of sIL-6R, which were abnormally low at baseline, increased to normal after therapy. The latter results pinpoint not only potential mediators of the systemic manifestations of POEMS syndrome with pulmonary hypertension but also relevant markers in patient follow-up. In this respect, IL-6 has been involved in the pathogenesis of multiple myeloma and Castleman's disease, and the interplay between abnormally high levels of IL-6 and abnormally low levels of its soluble receptor, deficiencies that corrected with therapy in this patient, appears to be particularly relevant to the pathogenic manifestations of POEMS syndrome with pulmonary hypertension. These findings are discussed in the context of our current knowledge of the pathogenesis of pulmonary hypertension and of potential new therapeutic modalities for POEMS syndrome with pulmonary hypertension.

KW - Cytokines

KW - Interleukin-6

KW - Plasma cell dyscrasias

KW - Soluble cytokine receptors

KW - Soluble interleukin-6 receptor

UR - http://www.scopus.com/inward/record.url?scp=0033399416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033399416&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 293

EP - 302

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 4

ER -